[go: up one dir, main page]

DK3012329T3 - METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY - Google Patents

METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY

Info

Publication number
DK3012329T3
DK3012329T3 DK15189527.3T DK15189527T DK3012329T3 DK 3012329 T3 DK3012329 T3 DK 3012329T3 DK 15189527 T DK15189527 T DK 15189527T DK 3012329 T3 DK3012329 T3 DK 3012329T3
Authority
DK
Denmark
Prior art keywords
heterozygosity
materials
methods
assessing loss
assessing
Prior art date
Application number
DK15189527.3T
Other languages
Danish (da)
Inventor
Victor Abkevich
Alexander Gutin
Kirsten Timms
Jerry Lanchbury
Original Assignee
Myriad Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myriad Genetics Inc filed Critical Myriad Genetics Inc
Application granted granted Critical
Publication of DK3012329T3 publication Critical patent/DK3012329T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/10—Ploidy or copy number detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2527/00—Reactions demanding special reaction conditions
    • C12Q2527/127—Reactions demanding special reaction conditions the enzyme inhibitor or activator used
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15189527.3T 2010-06-18 2011-06-17 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY DK3012329T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35650110P 2010-06-18 2010-06-18
EP11796544.2A EP2582847B1 (en) 2010-06-18 2011-06-17 Methods and materials for assessing loss of heterozygosity

Publications (1)

Publication Number Publication Date
DK3012329T3 true DK3012329T3 (en) 2017-11-20

Family

ID=45348911

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17194403.6T DK3327148T3 (en) 2010-06-18 2011-06-17 PROCEDURES FOR PREDICTING THE STATUS OF BRCA1 AND BRCA2 GENES IN A CANCER CELL
DK15189527.3T DK3012329T3 (en) 2010-06-18 2011-06-17 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
DK11796544.2T DK2582847T3 (en) 2010-06-18 2011-06-17 METHODS AND MATERIALS TO ASSESS loss of heterozygosity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK17194403.6T DK3327148T3 (en) 2010-06-18 2011-06-17 PROCEDURES FOR PREDICTING THE STATUS OF BRCA1 AND BRCA2 GENES IN A CANCER CELL

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11796544.2T DK2582847T3 (en) 2010-06-18 2011-06-17 METHODS AND MATERIALS TO ASSESS loss of heterozygosity

Country Status (6)

Country Link
US (7) US20120015050A1 (en)
EP (4) EP3327148B1 (en)
CA (1) CA2802882C (en)
DK (3) DK3327148T3 (en)
ES (3) ES2609931T3 (en)
WO (1) WO2011160063A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12129514B2 (en) 2009-04-30 2024-10-29 Molecular Loop Biosolutions, Llc Methods and compositions for evaluating genetic markers
WO2010126614A2 (en) 2009-04-30 2010-11-04 Good Start Genetics, Inc. Methods and compositions for evaluating genetic markers
EP3327148B1 (en) * 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
CA2807823C (en) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methods for predicting anti-cancer response
US9163281B2 (en) 2010-12-23 2015-10-20 Good Start Genetics, Inc. Methods for maintaining the integrity and identification of a nucleic acid template in a multiplex sequencing reaction
WO2012174378A2 (en) * 2011-06-17 2012-12-20 Myriad Genetics, Inc. Methods and materials for assessing allelic imbalance
WO2013058907A1 (en) 2011-10-17 2013-04-25 Good Start Genetics, Inc. Analysis methods
AU2012358244A1 (en) * 2011-12-21 2014-06-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
EP4462120A3 (en) 2012-02-23 2025-01-08 Children's Medical Center Corporation Methods for predicting response to parp inhibitors
US8209130B1 (en) 2012-04-04 2012-06-26 Good Start Genetics, Inc. Sequence assembly
US8812422B2 (en) 2012-04-09 2014-08-19 Good Start Genetics, Inc. Variant database
US10227635B2 (en) 2012-04-16 2019-03-12 Molecular Loop Biosolutions, Llc Capture reactions
US11091808B2 (en) 2012-06-07 2021-08-17 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
US20140127688A1 (en) * 2012-11-07 2014-05-08 Good Start Genetics, Inc. Methods and systems for identifying contamination in samples
CN105190656B (en) 2013-01-17 2018-01-16 佩索纳里斯公司 Method and system for genetic analysis
EP2971159B1 (en) 2013-03-14 2019-05-08 Molecular Loop Biosolutions, LLC Methods for analyzing nucleic acids
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
PT2981624T (en) * 2013-04-05 2020-03-23 Myriad Genetics Inc Methods and materials for assessing homologous recombination deficiency
EP3005200A2 (en) 2013-06-03 2016-04-13 Good Start Genetics, Inc. Methods and systems for storing sequence read data
EP3965111B8 (en) 2013-08-30 2025-06-11 Personalis, Inc. Methods for genomic analysis
WO2015051275A1 (en) 2013-10-03 2015-04-09 Personalis, Inc. Methods for analyzing genotypes
US10851414B2 (en) 2013-10-18 2020-12-01 Good Start Genetics, Inc. Methods for determining carrier status
EP3058096A1 (en) 2013-10-18 2016-08-24 Good Start Genetics, Inc. Methods for assessing a genomic region of a subject
US11149316B2 (en) 2013-12-09 2021-10-19 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (BRCA1/2) in human tumors
EP3094752A4 (en) * 2014-01-16 2017-08-16 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
WO2015175530A1 (en) 2014-05-12 2015-11-19 Gore Athurva Methods for detecting aneuploidy
ES3039109T3 (en) 2014-08-15 2025-10-17 Myriad Genetics Inc Methods and materials for assessing homologous recombination deficiency
WO2016025818A1 (en) 2014-08-15 2016-02-18 Good Start Genetics, Inc. Systems and methods for genetic analysis
WO2016040446A1 (en) 2014-09-10 2016-03-17 Good Start Genetics, Inc. Methods for selectively suppressing non-target sequences
US10429399B2 (en) 2014-09-24 2019-10-01 Good Start Genetics, Inc. Process control for increased robustness of genetic assays
EP3212808B1 (en) 2014-10-30 2022-03-02 Personalis, Inc. Methods for using mosaicism in nucleic acids sampled distal to their origin
EP3230472A4 (en) * 2014-12-08 2018-06-13 Myriad Genetics, Inc. Methods and materials for predicting response to niraparib
EP4095261B1 (en) 2015-01-06 2025-05-28 Molecular Loop Biosciences, Inc. Screening for structural variants
WO2016185406A1 (en) 2015-05-19 2016-11-24 Nadathur Estates Pvt. Ltd. Method for identification of a deficient brca1 function
WO2017178509A1 (en) 2016-04-12 2017-10-19 Xentech Methods for predicting sensibility to treatment with parp inhibitors in cancerous patients
US11299783B2 (en) 2016-05-27 2022-04-12 Personalis, Inc. Methods and systems for genetic analysis
AU2017290244B2 (en) 2016-06-29 2023-03-02 Tesaro, Inc. Methods of treating ovarian cancer
JP2020519621A (en) 2017-05-09 2020-07-02 テサロ， インコーポレイテッド Combination therapy to treat cancer
US11622961B2 (en) 2017-05-18 2023-04-11 Tesaro, Inc. Combination therapies for treating cancer
BR112020006286A2 (en) 2017-09-30 2020-10-20 Tesaro, Inc. combination therapies for cancer treatment
MA50618A (en) 2017-10-06 2020-08-12 Tesaro Inc POLYRHERAPIES AND THEIR USES
SG11202006147SA (en) 2017-12-27 2020-07-29 Tesaro Inc Methods of treating cancer
US11814750B2 (en) 2018-05-31 2023-11-14 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
US10801064B2 (en) 2018-05-31 2020-10-13 Personalis, Inc. Compositions, methods and systems for processing or analyzing multi-species nucleic acid samples
CA3120200A1 (en) * 2018-11-15 2020-05-22 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
JP7470787B2 (en) 2019-11-05 2024-04-18 パーソナリス，インコーポレイティド Estimation of tumor purity from a single sample
CN111105844B (en) * 2019-11-22 2023-06-06 广州金域医学检验集团股份有限公司 Somatic cell mutation classification method, apparatus, device, and readable storage medium
US12297508B2 (en) 2021-10-05 2025-05-13 Personalis, Inc. Customized assays for personalized cancer monitoring
WO2023196390A1 (en) * 2022-04-06 2023-10-12 Foundation Medicine, Inc. Aneuploidy biomarkers associated with response to anti-cancer therapies
EP4605937A1 (en) 2022-10-19 2025-08-27 Vib Vzw Method of determining loss of heterozygosity status of a tumor
WO2025078387A1 (en) 2023-10-10 2025-04-17 Vib Vzw Method of detecting loss of heterozygosity status of a tumor
WO2025078404A1 (en) 2023-10-10 2025-04-17 Vib Vzw Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
GB1432563A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GB1432562A (en) 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum co-ordination compounds
ES444380A1 (en) 1976-01-16 1977-06-16 Gosalvez Mario Novel anthracycline glycosides and methods of preparing the same
US4950738A (en) 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US5977082A (en) 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5177075A (en) 1988-08-19 1993-01-05 Warner-Lambert Company Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process
US5295944A (en) 1991-05-14 1994-03-22 Dana-Farber Cancer Institute Method for treating a tumor with ionizing radiation
ZA928771B (en) 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
US5858662A (en) * 1993-04-05 1999-01-12 University Of Utah Research Foundation Diagnosis of Williams syndrome and Williams syndrome cognitive profile by analysis of the presence or absence of a LIM-kinase gene
GB9806324D0 (en) 1998-03-24 1998-05-20 Pharmacia & Upjohn Spa Antitumour synergetic composition
US20030049613A1 (en) * 1998-08-17 2003-03-13 Manuel Perucho Methods for identifying somatic changes in genomic sequences useful for cancer diagnosis and prognosis
US6465177B1 (en) * 1998-10-26 2002-10-15 John Wayne Cancer Institute Detection of loss of heterozygosity in tumor and serum of melanoma patients
EP1339402B1 (en) 2000-12-01 2010-08-25 Eisai Inc. Azaphenanthridone derivatives and their use as parp inhibitors
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20050112604A1 (en) * 2003-03-14 2005-05-26 Akihide Fujimoto Loss of heterozygosity of the DNA markers in the 12q22-23 region
US7754684B2 (en) 2003-06-11 2010-07-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
US7485707B2 (en) 2003-07-02 2009-02-03 Solux Corporation Thermally stable crystalline epirubicin hydrochloride and method of making the same
NZ544989A (en) 2003-07-25 2009-10-30 Cancer Rec Tech Ltd Tricyclic PARP inhibitors
CA2535762A1 (en) 2003-08-13 2005-03-17 University Of South Florida Methods for inhibiting tumor cell proliferation
EP2280285A1 (en) * 2003-09-15 2011-02-02 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
WO2006128195A2 (en) * 2005-05-27 2006-11-30 Dana-Farber Cancer Institute Methods of diagnosing and treating cancer by detection of chromosomal abnormalities
CN101495459A (en) 2005-06-30 2009-07-29 比奥纽默里克药物公司 Monoazole ligand platinum analogs
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
EP2209375B1 (en) 2007-10-03 2014-08-27 Eisai Inc. Parp inhibitor compounds, compositions and methods of use
CN101917982B (en) * 2007-11-12 2013-03-20 彼帕科学公司 Treatment of breast cancer using 4-iodo-3-nitrobenzamide in combination with antineoplastic agents
CA2739459A1 (en) * 2008-10-31 2010-05-06 Abbott Laboratories Genomic classification of colorectal cancer based on patterns of gene copy number alterations
JP2011048332A (en) 2009-07-29 2011-03-10 Seiko Epson Corp Electrophoretic display element, electrophoretic display device, and electronic apparatus
EP3327148B1 (en) * 2010-06-18 2021-03-17 Myriad Genetics, Inc. Methods of predicting the status of brca1 and brca2 genes in a cancer cell
AU2012358244A1 (en) 2011-12-21 2014-06-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity

Also Published As

Publication number Publication date
CA2802882C (en) 2018-10-30
WO2011160063A3 (en) 2012-04-26
US20200399713A1 (en) 2020-12-24
EP2582847A4 (en) 2013-12-18
US20200010913A1 (en) 2020-01-09
US20120015050A1 (en) 2012-01-19
CA2802882A1 (en) 2011-12-22
US20250250643A1 (en) 2025-08-07
EP2582847A2 (en) 2013-04-24
EP3012329B1 (en) 2017-10-25
ES2609931T3 (en) 2017-04-25
ES2862331T3 (en) 2021-10-07
US11174519B2 (en) 2021-11-16
ES2655926T3 (en) 2018-02-22
EP3862440A1 (en) 2021-08-11
DK2582847T3 (en) 2016-12-19
EP3327148B1 (en) 2021-03-17
US20220205046A1 (en) 2022-06-30
US20150080260A1 (en) 2015-03-19
US20200087737A1 (en) 2020-03-19
EP2582847B1 (en) 2016-10-26
WO2011160063A2 (en) 2011-12-22
US10851425B2 (en) 2020-12-01
DK3327148T3 (en) 2021-04-12
EP3327148A1 (en) 2018-05-30
EP3012329A1 (en) 2016-04-27

Similar Documents

Publication Publication Date Title
DK3012329T3 (en) METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
DK2794907T4 (en) METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY
DK2598483T3 (en) AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS OF USING THESE
DK3329775T3 (en) Methods for synthesizing diarylthiohydantoin and diarylhydantoin compounds
DK2739293T3 (en) METHODS AND COMPOSITIONS FOR THE PRODUCTION OF VACCINAVIRUS
DK2643782T3 (en) SYSTEMS AND METHODS FOR ASSESSING COGNITIVE FUNCTION
DK2809795T3 (en) MATERIALS AND PROCEDURES FOR SYNTHESIS OF ERROR-MINIMIZED NUCLEIC ACID MOLECULES
DK2704703T3 (en) TRANSDERMAL COMPOSITIONS OF THE IBUPROFEN AND PROCEDURES FOR USING IT
DK2638149T3 (en) IMMORTALIZATION OF EPITHEL CELLS AND METHODS OF USE
DK2768321T3 (en) METHODS AND COMPOSITIONS FOR INDUCTION OF SATURITY
DK2558105T3 (en) BARDOXOLONMETHYL FOR TREATMENT OF OBESE
DK4289948T3 (en) METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION
DK2691443T3 (en) CONJUGIATED LIPOMERS AND USES OF THESE
DK3363901T3 (en) Compositions and methods for accurately identifying mutations
DK2625253T3 (en) System and method for roasting biomass
DK3202460T3 (en) ARYLMETHOXY-ISOINDOLIN DERIVATIVES AND COMPOSITIONS COMPREHENSIVE AND PROCEDURES FOR USE OF SAME
DK2594567T3 (en) HETEROCYCLIC ALKYNYLBENZENE COMPOUNDS AND USES THEREOF
DK2912174T3 (en) METHOD AND MATERIALS FOR INSULATING NUCLEIC ACID MATERIALS
DK2679354T3 (en) Arrangement and procedure for automated handling of subjects
DK2853265T3 (en) Methods for increasing the stabilization of hypoxia-inducible factor-1-alpha
DK3109326T3 (en) COMPOSITION AND PROCEDURE FOR NUCLEIC ACID SYNTHESIS AND AMPLIFICATION USING RT
DK2533761T3 (en) METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF AEROSOLS
DK2601611T3 (en) PROCEDURES FOR PREDICTING STABILITY AND MELTING TEMPERATURES FOR NUCLEIC ACID DUPLEXES
DK2445912T3 (en) New compound useful for the treatment of degenerative and inflammatory diseases
DK2663864T3 (en) PROCEDURE TO EVALUATE IMMEDIATE VARIETY AND APPLICATION OF THIS